BKM120 (NVP-BKM120) is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor and is currently being investigated in phase I clinical trials in solid tumors. Unlike other inhibitors, it does not inhibit the related kinases-mTOR and Vps34. BKM120 (NVP-BKM120) has shown significant cell growth inhibition and induction of apoptosis in a variety of tumor cell lines as well as in animal models, it decreases the cellular levels of p-Akt in mechanistic models and relevant tumor cell lines, as well as downstream effectors in a concentration-dependent and pathway-specific manner. Tested in a panel of 353 cell lines, BKM120 (NVP-BKM120) exhibited preferential inhibition of tumor cells bearing PIK3CA mutations, in contrast to either KRAS or PTEN mutant models. BKM120 treatment significantly inhibits tumor growth in vivo and prolongs the survival of myeloma-bearing mice. In addition, it shows synergistic cytotoxicity with dexamethasone in dexamethasone-sensitive MM cells. BKM120 (NVP-BKM120) behaves synergistically when combined with either targeted agents such as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide.
Cancer Biol Ther. 2018 May 25;1-20.
Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent
BKM120 (Buparlisib) purchased from AbMole
BioRxiv. 2017 July 18;1-45.
PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors.
BKM120 (Buparlisib) purchased from AbMole
|Source||Cancer Biol Ther (2018). Figure 3. BKM120 (AbMole BioScience)|
|Cell Lines||RCC 786-0 cell line|
|Incubation Time||48 or 72 h|
|Results||These IC50 values were obviously lower than that of the compounds BEZ235 and BKM120, which may be promising candidates for development as new drugs targeting the PI3K pathway.|
|Source||BioRxiv (2017). Figure 6. BKM-120 (Abmole Bioscience, Hong-Kong, China)|
|Cell Lines||8505c cells|
|Results||In this case, BKM-120 similarly abrogated the paradoxical effect seen in OCUT-2, demonstrating that the phenomenon observed is unlikely to be caused by a possible off-target effect of GDC-0941 but was rather specific to its inhibitory effect on PI3’K activity.|
|Cell lines||Rat1-myr-p110α, β, and δ and TSC1−/−-null MEFs cells|
|Preparation method||A total of 2 × 106 cells were seeded per 10-cm dish. Eighteen hours later, the medium was discarded and replaced with 10 mL of fresh medium containing the test items. Unless specified in the figure legend, the incubation period was 30 minutes. For agonist activation, cells were first starved for 18 hours in 9 mL of medium containing only 0.05% FBS. Then cells were pretreated for 30 minutes by addition of 1 mL of medium containing the test items and subsequently stimulated for 10 minutes with the agonist (final concentrations: 50 ng/mL for PDGF, 100 ng/mL for epidermal growth factor (EGF), 60 ng/mL interleukin (IL)-4, and 1 μmol/L anisomycin). Cells were washed twice, lysed, and processed by Western blot analysis as described|
|Incubation time||30 min|
|Animal models||Orthotopic BT-474 tumors model with female Harlan nude (HsdNpa:Athymic Nude-nu) mice (8–10 weeks of age)|
|Formulation||formulated in NMP/PEG300 (10/90, v/v)|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥80 mg/mL|
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
Ren et al. Cancer Lett. 2012 Jul 7. PMID: 22781393.
Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations.
Brachmann et al. Mol Cancer Ther. 2012 Aug;11(8):1747-57. PMID: 22653967.
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Mueller et al. Cancer Chemother Pharmacol. 2012 Jun;69(6):1601-15. PMID: 22543857.
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell et al. J Clin Oncol. 2012 Jan 20;30(3):282-90. PMID: 22162589.
|Related PI3K Products|
Linperlisib, also known as YY-20394 and PI3Kδ-IN-2, is a potent and selective PI3Kδ inhibitor.
Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor with IC50 of 11 nM.
Seletalisib (UCB5857) is a potent and selective PI3Kδ inhibitor, with IC50 of 12 nM.
Glaucocalyxin A is an ent-kauranoid diterpene from Rabdosia japonica var.
BAY1082439 is an orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha and beta isoforms with potential antineoplastic activity.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.